Close Menu

NEW YORK (GenomeWeb News) – Immunodiagnostic Systems has licensed the right to use new biomarkers developed by Biosignatures for use in immunoassay diagnostic test kits for kidney diseases, IDS said today.

The agreement covers the proteomics-based biomarker technology developed by Biosignatures, a Newcastle, UK-based company that spun out from Nonlinear Dynamics. The initial focus of the license agreement will cover kidney diseases and related conditions and will use the IDS iSYS platform, IDS said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.